|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Oral, seldom IM|
|Elimination half-life||~20 hours|
|Excretion||In feces and urine (metabolites), unchanged drug only 1%|
|Chemical and physical data|
|Molar mass||328.47 g/mol|
|3D model (JSmol)|
Levomepromazine, also known as methotrimeprazine, is a phenothiazine neuroleptic drug. Brand names include Nozinan, Levoprome, Detenler, Hirnamin, Levotomin, Neurocil. It is a low-potency antipsychotic (approximately half as potent as chlorpromazine) with strong analgesic, hypnotic and antiemetic properties that is primarily used in palliative care.
Serious side effects include tardive dyskinesia, akathisia, abnormalities in the electrical cycle of the heart, low blood pressure and the potentially fatal neuroleptic malignant syndrome.
As is typical of phenothiazine antipsychotics, levomepromazine is a "dirty drug", that is, it exerts its effects by blocking a variety of receptors, including adrenergic receptors, dopamine receptors, histamine receptors, muscarinic acetylcholine receptors and serotonin receptors.
It can be used as an analgesic for moderate to severe pain in non-ambulant patients (the latter being because of its strong sedative effects).
Levomepromazine is frequently prescribed and valued worldwide in palliative care medicine for its multimodal action, to treat intractable nausea or vomiting, and for severe delirium/agitation in the last days of life. Palliative care physicians will commonly prescribe it orally or via subcutaneous syringe drivers in combination with opioid analgesics such as hydromorphone.
Levomepromazine is used for the treatment of psychosis, particularly those of schizophrenia, and manic phases of bipolar disorder. It should only be used with caution in the treatment of agitated depressions, as it can cause akathisia as a side effect, which could worsen the agitation.A 2010 systematic review compared the efficacy of levomepromazine with atypical antipsychotic drugs:
The most common side effect is akathisia. Levomepromazine has prominent sedative and anticholinergic/sympatholytic effects (dry mouth, hypotension, sinus tachycardia, night sweats) and may cause weight gain. These side effects normally preclude prescribing the drug in doses needed for full remission of schizophrenia, so it has to be combined with a more potent antipsychotic. In any case, blood pressure and EKG should be monitored regularly.
A rare but life-threatening side effect is neuroleptic malignant syndrome (NMS). The symptoms of NMS include muscle stiffness, convulsions and fever.
- Brayfield, A, ed. (13 December 2013). "Levomepromazine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 12 May 2014.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- "Levomepromazine". Farmacotherapeutisch Kompas (in Dutch). Retrieved 5 October 2016.
- Sivaraman, P; Rattehalli, R; Jayaram, M (2010). "Levomepromazine for schizophrenia". The Cochrane Database of Systematic Reviews. 10: CD007779.pub2. doi:10.1002/14651858.CD007779.pub2. PMC 3283151
. PMID 20927765.
- PubChem Substance Summary: Levomepromazine National Center for Biotechnology Information.
- NOZINAN - Lévomépromazine Doctissimo Guides des Medicaments
- Grampians Palliative Care Team Publication May 2010 (Victoria, Australia)
- Palliative Care Guidelines, Scotland, UK